China Health Group Inc. has announced the successful hosting of the "AI-RWS Real-World Study Summit Forum" in Shanghai. During the event, more than ten AI-driven real-world study (AI-RWS) projects were discussed. The Group plans to develop a world database in China that will include 100,000 patients over the next five years. The focus will be on researching non-pharmacological interventions and combination therapies, providing crucial data for innovative drug registration and post-marketing safety re-evaluation. The Group holds exclusive rights in China for clinical research experiments involving Xienka Microchip Nanoparticles and Xienmei Flash Tablets. Xienka Microchip Nanoparticles, a key product in this research, is designed for the treatment of mild to moderate dementia and is covered by national medical insurance. The results of these studies were not specified to be presented at the forum, indicating they may be shared in future updates.